Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype

Olaoye, O; Watson, P.; Nawar, N.; Geletu, M.; Sedighi, A.; Bukhari, S.; Raouf, Y.; Manaswiyoungkul, P.; Erdogan, F.; Abdeldayem, A.; Cabral, A.; Hassan, M.; Toutah, K.; Shouksmith, A.; Gawel, J.; Israelian, J.; Radu, T.; Kachhiyapatel, N.; de Araujo, E.; Christianson, D.; Gunning, P.

doi:10.1021/acs.jmedchem.0c01922

Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype

Journal Article · 01 January 2022 · Journal of Medicinal Chemistry

DOI:https://doi.org/10.1021/acs.jmedchem.0c01922· OSTI ID:1783992

Olaoye, O; Watson, P.; Nawar, N.; Geletu, M.; Sedighi, A.; Bukhari, S.; Raouf, Y.; Manaswiyoungkul, P.; Erdogan, F.; Abdeldayem, A.; Cabral, A.; Hassan, M.; Toutah, K.; Shouksmith, A.; Gawel, J.; Israelian, J.; Radu, T.; Kachhiyapatel, N.; de Araujo, E.; Christianson, D. more »

Research Organization:: Brookhaven National Lab. (BNL), Upton, NY (United States)

Sponsoring Organization:: ~OTHER

DOE Contract Number:: SC0012704

OSTI ID:: 1783992

Report Number(s):: BNL-221523-2021-JACI

Journal Information:: Journal of Medicinal Chemistry, Vol. 64, Issue 5

Country of Publication:: United States

Language:: English

References (58)

HDAC6 as a target for antileukemic drugs in acute myeloid leukemia Hackanson, Björn; Rimmele, Leander; Benkißer, Marco Leukemia Research, Vol. 36, Issue 8 https://doi.org/10.1016/j.leukres.2012.02.026	journal	August 2012
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma Santo, Loredana; Hideshima, Teru; Kung, Andrew L. Blood, Vol. 119, Issue 11 https://doi.org/10.1182/blood-2011-10-387365	journal	March 2012
HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma Wang, Zhihao; Tang, Fang; Hu, Pengchao Oncology Reports, Vol. 36, Issue 1 https://doi.org/10.3892/or.2016.4811	journal	May 2016
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight Ho, Terence C. S.; Chan, Alex H. Y.; Ganesan, A. Journal of Medicinal Chemistry, Vol. 63, Issue 21 https://doi.org/10.1021/acs.jmedchem.0c00830	journal	July 2020
Role of HDACs in normal and malignant hematopoiesis Wang, Pan; Wang, Zi; Liu, Jing Molecular Cancer, Vol. 19, Issue 1 https://doi.org/10.1186/s12943-019-1127-7	journal	January 2020
Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present) Zhao, Chunlong; Dong, Hang; Xu, Qifu Expert Opinion on Therapeutic Patents, Vol. 30, Issue 4 https://doi.org/10.1080/13543776.2020.1725470	journal	February 2020
Histone deacetylases, acetoin utilization proteins and acetylpolyamine amidohydrolases are members of an ancient protein superfamily Leipe, D. D.; Landsman, D. Nucleic Acids Research, Vol. 25, Issue 18 https://doi.org/10.1093/nar/25.18.3693	journal	September 1997
Molecular Evolution of the Histone Deacetylase Family: Functional Implications of Phylogenetic Analysis Gregoretti, IvanV; Lee, Yun-Mi; Goodson, Holly V. Journal of Molecular Biology, Vol. 338, Issue 1 https://doi.org/10.1016/j.jmb.2004.02.006	journal	April 2004
HDAC6 inhibitors: Translating genetic and molecular insights into a therapy for axonal CMT Rossaert, Elisabeth; Van Den Bosch, Ludo Brain Research, Vol. 1733 https://doi.org/10.1016/j.brainres.2020.146692	journal	April 2020
Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma Auzmendi-Iriarte, Jaione; Saenz-Antoñanzas, Ander; Mikelez-Alonso, Idoia Cell Death & Disease, Vol. 11, Issue 6 https://doi.org/10.1038/s41419-020-2586-x	journal	June 2020
Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis Park, Jin Kyun; Jang, Yu Jin; Oh, Bo Ram Arthritis Research & Therapy, Vol. 22, Issue 1 https://doi.org/10.1186/s13075-020-02258-0	journal	July 2020
HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination Boyault, C.; Sadoul, K.; Pabion, M. Oncogene, Vol. 26, Issue 37 https://doi.org/10.1038/sj.onc.1210614	journal	August 2007
HDAC6 at Crossroads of Infection and Innate Immunity Moreno-Gonzalo, Olga; Mayor, Federico; Sánchez-Madrid, Francisco Trends in Immunology, Vol. 39, Issue 8 https://doi.org/10.1016/j.it.2018.05.004	journal	August 2018
Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models: Activity of HDAC6 inhibitors in cancer models Depetter, Yves; Geurs, Silke; De Vreese, Rob International Journal of Cancer, Vol. 145, Issue 3 https://doi.org/10.1002/ijc.32169	journal	February 2019
Histone deacetylase 6 structure and molecular basis of catalysis and inhibition Hai, Yang; Christianson, David W. Nature Chemical Biology, Vol. 12, Issue 9 https://doi.org/10.1038/nchembio.2134	journal	July 2016
Structural insights into HDAC6 tubulin deacetylation and its selective inhibition Miyake, Yasuyuki; Keusch, Jeremy J.; Wang, Longlong Nature Chemical Biology, Vol. 12, Issue 9 https://doi.org/10.1038/nchembio.2140	journal	July 2016
Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation Haggarty, S. J.; Koeller, K. M.; Wong, J. C. Proceedings of the National Academy of Sciences, Vol. 100, Issue 8 https://doi.org/10.1073/pnas.0430973100	journal	April 2003
Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally Zhang, Yu; Kwon, SoHee; Yamaguchi, Teppei Molecular and Cellular Biology, Vol. 28, Issue 5 https://doi.org/10.1128/mcb.01154-06	journal	March 2008
Critical role of the HDAC6–cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect Messaoudi, Kahia; Ali, Ashfaq; Ishaq, Rameez Nature Communications, Vol. 8, Issue 1 https://doi.org/10.1038/s41467-017-01690-2	journal	November 2017
A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019) Shen, Sida; Kozikowski, Alan P. Expert Opinion on Therapeutic Patents, Vol. 30, Issue 2 https://doi.org/10.1080/13543776.2019.1708901	journal	December 2019
Multicomponent Synthesis and Binding Mode of Imidazo[1,2- a ]pyridine-Capped Selective HDAC6 Inhibitors Mackwitz, Marcel K. W.; Hamacher, Alexandra; Osko, Jeremy D. Organic Letters, Vol. 20, Issue 11 https://doi.org/10.1021/acs.orglett.8b01118	journal	May 2018
Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability Jochems, Jeanine; Boulden, Janette; Lee, Bridgin G. Neuropsychopharmacology, Vol. 39, Issue 2 https://doi.org/10.1038/npp.2013.207	journal	August 2013
Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation Vergani, Barbara; Sandrone, Giovanni; Marchini, Mattia Journal of Medicinal Chemistry, Vol. 62, Issue 23 https://doi.org/10.1021/acs.jmedchem.9b01194	journal	November 2019
Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer Shouksmith, Andrew E.; Shah, Fenil; Grimard, Michelle L. Journal of Medicinal Chemistry, Vol. 62, Issue 5 https://doi.org/10.1021/acs.jmedchem.8b01957	journal	February 2019
Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity Porter, Nicholas J.; Osko, Jeremy D.; Diedrich, Daniela Journal of Medicinal Chemistry, Vol. 61, Issue 17 https://doi.org/10.1021/acs.jmedchem.8b01013	journal	April 2018
Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor Shen, Sida; Svoboda, Michal; Zhang, Guangming ACS Medicinal Chemistry Letters, Vol. 11, Issue 5 https://doi.org/10.1021/acsmedchemlett.9b00560	journal	January 2020
Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors Porter, Nicholas J.; Mahendran, Adaickapillai; Breslow, Ronald Proceedings of the National Academy of Sciences, Vol. 114, Issue 51 https://doi.org/10.1073/pnas.1718823114	journal	December 2017
PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia Gawel, Justyna M.; Shouksmith, Andrew E.; Raouf, Yasir S. European Journal of Medicinal Chemistry, Vol. 201 https://doi.org/10.1016/j.ejmech.2020.112411	journal	September 2020
Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia Shouksmith, Andrew E.; Gawel, Justyna M.; Nawar, Nabanita ACS Medicinal Chemistry Letters, Vol. 11, Issue 1 https://doi.org/10.1021/acsmedchemlett.9b00471	journal	December 2019
Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6 Osko, Jeremy D.; Christianson, David W. Biochemistry, Vol. 58, Issue 49 https://doi.org/10.1021/acs.biochem.9b00934	journal	November 2019
Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6 Osko, Jeremy D.; Christianson, David W. Bioorganic & Medicinal Chemistry Letters, Vol. 30, Issue 8 https://doi.org/10.1016/j.bmcl.2020.127023	journal	April 2020
Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities Ali, Ahmed M.; Gómez-Biagi, Rodolfo F.; Rosa, David A. ChemMedChem, Vol. 11, Issue 8 https://doi.org/10.1002/cmdc.201600021	journal	March 2016
Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases Porter, Nicholas J.; Christianson, David W. Current Opinion in Structural Biology, Vol. 59 https://doi.org/10.1016/j.sbi.2019.01.004	journal	December 2019
Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6 Porter, Nicholas J.; Wagner, Florence F.; Christianson, David W. Biochemistry, Vol. 57, Issue 26 https://doi.org/10.1021/acs.biochem.8b00367	journal	May 2018
Carbonic Anhydrase: Evolution of the Zinc Binding Site by Nature and by Design Christianson, David W.; Fierke, Carol A. Accounts of Chemical Research, Vol. 29, Issue 7 https://doi.org/10.1021/ar9501232	journal	January 1996
Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma Ray, A.; Das, D. S.; Song, Y. Leukemia, Vol. 32, Issue 3 https://doi.org/10.1038/leu.2017.322	journal	November 2017
Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study) Yee, Andrew J.; Bensinger, William; Voorhees, Peter M. Blood, Vol. 126, Issue 23 https://doi.org/10.1182/blood.v126.23.3055.3055	journal	December 2015
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma Hideshima, Teru; Qi, Jun; Paranal, Ronald M. Proceedings of the National Academy of Sciences, Vol. 113, Issue 46 https://doi.org/10.1073/pnas.1608067113	journal	October 2016
HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma Wang, Zhihao; Hu, Pengchao; Tang, Fang Cancer Letters, Vol. 379, Issue 1 https://doi.org/10.1016/j.canlet.2016.06.001	journal	August 2016
Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia Maharaj, Kamira; Powers, John J.; Achille, Alex Blood Advances, Vol. 2, Issue 21 https://doi.org/10.1182/bloodadvances.2018020065	journal	November 2018
Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bendamustine Is Effective in Preclinical Studies in Lymphoma Cell Lines Cosenza, Maria; Civallero, Monica; Quayle, Steven N. Blood, Vol. 128, Issue 22 https://doi.org/10.1182/blood.v128.22.2772.2772	journal	December 2016
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine Cosenza, Maria; Civallero, Monica; Marcheselli, Luigi Apoptosis, Vol. 22, Issue 6 https://doi.org/10.1007/s10495-017-1364-4	journal	March 2017
HDAC inhibitors still need a home run, despite recent approval Guha, Malini Nature Reviews Drug Discovery, Vol. 14, Issue 4 https://doi.org/10.1038/nrd4583	journal	April 2015
HDAC6 is a microtubule-associated deacetylase Hubbert, Charlotte; Guardiola, Amaris; Shao, Rong Nature, Vol. 417, Issue 6887 https://doi.org/10.1038/417455a	journal	May 2002
Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells Catley, Laurence; Weisberg, Ellen; Kiziltepe, Tanyel Blood, Vol. 108, Issue 10 https://doi.org/10.1182/blood-2006-04-016055	journal	November 2006
Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers Sanchez, Gilson J.; Richmond, Phillip A.; Bunker, Eric N. Nucleic Acids Research, Vol. 46, Issue 4 https://doi.org/10.1093/nar/gkx1225	journal	December 2017
Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas Lue, Jennifer K.; Prabhu, Sathyen A.; Liu, Yuxuan Clinical Cancer Research, Vol. 25, Issue 17 https://doi.org/10.1158/1078-0432.ccr-18-3989	journal	April 2019
The role of cellular reactive oxygen species in cancer chemotherapy Yang, Haotian; Villani, Rehan M.; Wang, Haolu Journal of Experimental & Clinical Cancer Research, Vol. 37, Issue 1 https://doi.org/10.1186/s13046-018-0909-x	journal	November 2018
NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells Jayavelu, A. K.; Müller, J. P.; Bauer, R. Leukemia, Vol. 30, Issue 2 https://doi.org/10.1038/leu.2015.234	journal	August 2015
Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia Zhou, Fuling; Shen, Qiang; Claret, François X. Journal of Leukocyte Biology, Vol. 94, Issue 3 https://doi.org/10.1189/jlb.0113006	journal	May 2013
Histone Deacetylase Inhibitors as Anticancer Drugs Eckschlager, Tomas; Plch, Johana; Stiborova, Marie International Journal of Molecular Sciences, Vol. 18, Issue 7 https://doi.org/10.3390/ijms18071414	journal	July 2017
Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism Debeb, Bisrat G.; Lacerda, Lara; Larson, Richard Oncotarget, Vol. 7, Issue 19 https://doi.org/10.18632/oncotarget.8631	journal	April 2016
Romidepsin targets multiple survival signaling pathways in malignant T cells Valdez, B. C.; Brammer, J. E.; Li, Y. Blood Cancer Journal, Vol. 5, Issue 10 https://doi.org/10.1038/bcj.2015.83	journal	October 2015
Blood stability testing: European Bioanalysis Forum view on current challenges for regulated bioanalysis Freisleben, Achim; Brudny-Klöppel, Margarete; Mulder, Hans Bioanalysis, Vol. 3, Issue 12 https://doi.org/10.4155/bio.11.121	journal	June 2011
Reduction of hydroxamic acids to the corresponding amides catalyzed by rabbit blood Sugihara, K.; Kitamura, S.; Ohta, S. Xenobiotica, Vol. 30, Issue 5 https://doi.org/10.1080/004982500237479	journal	January 2000
Controlling Plasma Stability of Hydroxamic Acids: A MedChem Toolbox Hermant, Paul; Bosc, Damien; Piveteau, Catherine Journal of Medicinal Chemistry, Vol. 60, Issue 21 https://doi.org/10.1021/acs.jmedchem.7b01444	journal	October 2017
Hydroxamates: Relationships between Structure and Plasma Stability Flipo, Marion; Charton, Julie; Hocine, Akila Journal of Medicinal Chemistry, Vol. 52, Issue 21 https://doi.org/10.1021/jm900648x	journal	November 2009
A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinostat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) with advanced solid tumors (AST). Gordon, Michael S.; Shapiro, Geoffrey; Sarantopoulos, John Journal of Clinical Oncology, Vol. 36, Issue 15_suppl https://doi.org/10.1200/JCO.2018.36.15_suppl.2547	journal	May 2018

Similar Records

Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors

Journal Article · 2022 · Journal of Medicinal Chemistry · OSTI ID:1783955

Vögerl, K; Ong, N.; Senger, J.; +13 more

Binding of inhibitors to active-site mutants of CD1, the enigmatic catalytic domain of histone deacetylase 6

Journal Article · 2022 · Acta Crystallographica Section F Structural Biology Communications · OSTI ID:1783946

Osko, J; Christianson, D.

Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6

Journal Article · 2019 · Biochemistry · OSTI ID:1578241

Osko, Jeremy D.; Christianson, David W.

Related Subjects

99 GENERAL AND MISCELLANEOUS

Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype

Citation Formats

References (58)

Similar Records

Related Subjects